Summit Therapeutics annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics Stock-Based Compensation Growth & History (SMMT)
Summit Therapeutics's stock-based compensation was $732.4M for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $732.4M | $681.4M | +1336.65% |
| 2024 | 2024-12-31 | $51.0M | $36.9M | +261.36% |
| 2023 | 2023-12-31 | $14.1M | $2.2M | +18.08% |
| 2022 | 2022-12-31 | $11.9M | −$856,000 | −6.69% |
| 2021 | 2021-12-31 | $12.8M | $11.0M | +625.03% |
| 2020 | 2020-12-31 | $1.8M | $921,000 | +108.99% |
| 2019 | 2019-12-31 | $845,000 | — | — |
| 2018 | 2019-01-31 | $6.3M | — | — |
Summit Therapeutics quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $68.7M | −$410.1M | −85.65% |
| Q1 2026 | 2026-03-31 | $72.8M | $61.7M | +556.01% |
| Q4 2025 | 2025-12-31 | $111.8M | $100.8M | +914.79% |
| Q3 2025 | 2025-09-30 | $130.8M | $111.4M | +575.03% |
| Q2 2025 | 2025-06-30 | $478.8M | $467.7M | +4218.04% |
| Q1 2025 | 2025-03-31 | $11.1M | $1.6M | +16.71% |
| Q4 2024 | 2024-12-31 | $11.0M | $2.3M | +25.84% |
| Q3 2024 | 2024-09-30 | $19.4M | $18.7M | +2647.66% |
| Q2 2024 | 2024-06-30 | $11.1M | $9.2M | +491.36% |
| Q1 2024 | 2024-03-31 | $9.5M | $6.7M | +242.59% |
| Q4 2023 | 2023-12-31 | $8.8M | $6.1M | +229.31% |
| Q3 2023 | 2023-09-30 | $705,000 | −$2.1M | −74.80% |
| Q2 2023 | 2023-06-30 | $1.9M | −$621,000 | −24.88% |
| Q1 2023 | 2023-03-31 | $2.8M | −$1.2M | −30.56% |
| Q4 2022 | 2022-12-31 | $2.7M | −$3.0M | −52.70% |
| Q3 2022 | 2022-09-30 | $2.8M | $154,000 | +5.82% |
| Q2 2022 | 2022-06-30 | $2.5M | −$1.2M | −32.03% |
| Q1 2022 | 2022-03-31 | $4.0M | $3.1M | +360.37% |
| Q4 2021 | 2021-12-31 | $5.6M | $5.0M | +872.32% |
| Q3 2021 | 2021-09-30 | $2.6M | $2.3M | +632.41% |
| Q2 2021 | 2021-06-30 | $3.7M | $3.1M | +592.83% |
| Q1 2021 | 2021-03-31 | $868,000 | $571,000 | +192.26% |
| Q4 2020 | 2020-12-31 | $578,000 | — | — |
| Q3 2020 | 2020-09-30 | $361,000 | $117,000 | +47.95% |
| Q2 2020 | 2020-06-30 | $530,000 | — | — |
| Q1 2020 | 2020-03-31 | $297,000 | — | — |
| Q3 2019 | 2019-09-30 | $244,000 | — | — |
Summit Therapeutics stock-based compensation trends
Over the last five fiscal years, Summit Therapeutics's stock-based compensation increased from $1.8M to $732.4M, a change of $730.7M. The latest reported quarter, Q2 2026, shows $68.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗